RESULTS: 920 paired WT and MT peptides were predicted by bioinformatic screening based on the criteria of higher affinity of MT peptides and lower affinity of WT peptides to HLA-A2 molecules. 60 paired peptides were synthesized with the highest affinity and expression frequency and subjected to T2 cells based validation. Among them, 12 MT peptides from 12 individual genes exhibited higher and stronger affinity to HLA-A2 molecules when compared to WT counterparts. Importantly, it was shown that bladder cancer patients exhibited higher responsiveness to MT peptides than to WT peptides. The average number of peptide-specific IFNg spots from 26 HLA-A2 positive bladder cancer patients upon MT peptide stimulation was dramatically higher than that upon WT stimulation (P[0.000). The clinical association analysis revealed that MT peptide specific T cell responsiveness was negatively correlated to C-reactive protein (r [-0.431, P<0.05) and thrombocytocrit (r [-0.499, P<0.05). WT peptide-specific T cell responses, on the other hand, was more related to platelet count (r[-0.428, P<0.05) and thrombocytocrit (r [-0.596, P<0.05).
INTRODUCTION AND OBJECTIVES: Despite preventing recurrence of non-muscle invasive bladder cancer (BC), the chemotherapeutic drug Mitomycin C(MMC) is effective only in a proportion of patients. We speculated that treatment success might not only rely on MMC cytotoxic potential, but also on its ability to trigger immunogenic cell death (ICD) . In this study, we assessed MMC-induced ICD in a panel of BC cell lines and patient-derived samples. Moreover, we investigated the molecular changes in ICDresponsive versus not-responsive BC cells to identify potential underlying mechanisms of MMC efficacy.
METHODS: Human BC cell lines and cancer samples (stage Ta, T1 retrieved during transurethral resection-ICH-MIM-01) were treated or not with MMC for 1h and expression of ICD markers was then assessed by flow cytometry and enzyme-linked immunosorbent assay. The ability of dendritic cells (DCs) to phagocytose tumor cells and undergo maturation was analyzed after 2h and 24h coculture by flow cytometry. Illumina mRNA sequencing was used to screen for differentially expressed genes between ICD-responsive and not responsive BC cell lines.
RESULTS: Treatment with MMC fostered ICD in BC cells by inducing endoplasmic reticulum stress response, increased secretion of the damage signal high-mobility-group box 1 (HMGB1), and augmented DC-mediated phagocytic clearance of treated tumor cells compared to untreated cells. By scoring MMC-induced ICD responses in a panel of different BC cell lines we identified ICD-responsive and ICD-not responsive cells, which we analyzed by mRNA sequencing. We found an upregulation of apoptosis and TNF-signaling pathways and a downregulation of protein processing in ICD-responsive cells, indicating that pro-apoptotic signals and local inflammation are necessary for MMC-induced ICD. Consistently, ex-vivo treatment of patient-derived tumors with MMC induced expression of ICD markers in some of the samples. Importantly, only BC cells and tumor tissues undergoing ICD upon MMC treatment, as measured by increased secretion of HMGB1 and pro-inflammatory molecules, could promote DC maturation, a crucial step for proper priming of adaptive immunity.
CONCLUSIONS: Overall, we showed a novel immune-related mechanism of action of MMC that may be exploited to optimize bladder cancer management and identify possible ICD-related biomarkers.
antimicrobial peptides (AMPs) cause BCG failure and unwanted side effects. Here, we generated genetically modified BCG strains with improved immunotherapeutic effects by adding genes that confer evasion of AMPs.
METHODS: We constructed recombinant BCG (rBCG) strains expressing Streptococcal inhibitor of complement (Sic), which confers resistance to human a-defensin-1 and cathelicidin, and d-alanyl carrier protein ligase (dltA), which confers resistance to cationic AMPs. Sic and dltA were separately cloned into the pMV306 plasmid and introduced into BCG via electroporation. Then, the efficacy of the rBCGs was tested in a growth inhibition assay using two bladder cancer cell lines (5637, T24).
RESULTS: We confirmed the presence of cDNA segments corresponding to the Sic and dltA genes in total mRNA of the rBCG strains containing Sic (rBCG-Sic) and dltA (rBCG-dltA), and these rBCGs showed higher survival against AMPs. The growth inhibitory effects of rBCGs on bladder cancer cells were significantly enhanced compared to those of the parent BCG, and THP-1 migration also increased. After 8 h of infection, the levels of internalization were higher in rBCG-infected bladder cancer cells than in BCG-infected cells, and cells infected with rBCGs showed increased release of antitumor cytokines, such as IL-6/12, TNF-a, and INF-g, resulting in inhibition of bacterial killing and immune modulation via antimicrobial peptides.
CONCLUSIONS: rBCG-Sic and rBCG-dltA can effectively evade BCG-stimulated AMPs may be significantly improved immunotherapeutic tools to treat bladder cancer. 
INTRODUCTION AND OBJECTIVES:
Bladder cancer is one of the most common malignant tumors in the urinary system. Intravesical instillation of BCG has been proved to reduce the recurrence of bladder cancer and prevents the progression of cancer, which in turn improves survival rate and prolongs survival time. However, repetitive irrigation of large-dose BCG leads to various complications. Moreover, 30%-50% patients have low responses to BCG therapy, limiting its clinical applications in bladder cancer. In this study, we have introduced NY-ESO-1, a well-known tumor antigen, into BCG to construct recombinant BCG stains (rBCG::NY-ESO-1). The immunogenicities of the rBCG strains were evaluated in mouse vaccination model. METHODS: Human-derived NY-ESO-1 cDNA was amplified and inserted into the shuttle expression vector pMV261. The recombinant plasmids pMV261-NY-ESO-1 were transformed into BCG by electroporation. The recombinant BCG strains were screened and the expression of NY-ESO-1 was verified by Western blot. The C57BL/6 mice were immunized by subcutaneous injection with rBCG:NY-ESO-1 and BCG at a dose of 5Â10^6 CFU per 100µl. Immunological profiles were evaluated at 4 weeks by Enzyme-linked Immunospot Assay (ELISPOT) and flow cytometry (FCM).
RESULTS: One-dose injection of rBCG::NY-ESO-1 induced both PPD and NY-ESO-1 specific IFNg release upon antigen stimulation ex vivo whereas BCG vaccination induced comparable PPD-specific responses and less NY-ESO-1-specific responses. In addition, rBCG vaccinated mice displayed more effect CD8þ T cells and NY-ESO-1-specific IFNgþCD8þ T cells. Meanwhile, both NY-ESO-1 and PPD-specific IL-10 producing CD8þT cells were decreased in rBCG::NY-ESO-1 vaccinated mice when compared to BCG vaccinated group. Mice vaccinated with rBCG showed less frequencies of Treg at 4 weeks post vaccination.
CONCLUSIONS: Vaccination of rBCG containing NY-ESO-1 can induce both PPD and NY-ESO-1 specific cellular responses where NY-ESO-1 specific CD8 T cells exhibit more functional effects. Introduction of NY-ESO-1 into BCG thus orchestrates NY-ESO-1-specific immune responses and immune modulator of BCG, which might increase the efficacy of intravesical instillation of BCG against bladder cancer.
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MP63-20 STANDARD ANTICANCER AGENTS INCREASE THE CYTOTOXICITY OF HUMAN Vg9Vd2T CELL VIA UPREGULATION OF NKG2D LIGANDS IN BLADDER CANCER CELLS
Teruki Shimizu*, Osaka, Japan; Masatsugu Miyashita, Atsuko Fujihara, Fumiya Hongo, Osamu Ukimura, Eishi Ashihara, Kyoto, Japan INTRODUCTION AND OBJECTIVES: In clinical trials, Zoledronic acid (ZOL) pretreatment in cancer cells is widely used to improve the efficacy of human gdT cell immunotherapy.We herein provide new strategies for the enhancement of gdT cell function by anticancer pretreatment in urinary bladder cancer (UBC) cells. The aim of this study was whether pretreatment of cancer cells with standard anticancer agents would increase the cytotoxicity of gdT cells.
METHODS: The surface expression of NKG2D, TCRVg9, TCRVd2 and the intracellular levels of perforin and GranzymeB were examained. In in vitro assays, UBC cell lines T24, TCCSUP, and UMUC3 were used. Flow cytometric analysis of CFSE /propidium iodide (PI) staining was used in in vitro cytotoxicity assays. Imaging of cancer cells lysed by human gdT cell was captured by laser microscopy. UBC cells were treated with various standard anticancer agents at sub-lethal concentrations, including cisplatin (CDDP), gemcitabine (GEM), methotrexate (MTX), vinblastine (VBL), adriamycin (ADR), and mitomycin C (MMC). The expressions of MICA/B, ULBP1, and ULBP2/5/6 in UBC cells were investigated. In in vivo experiments, the efficacy of intravesical administration of ex vivo-expanded gdT cells was examined in an orthotopic xenograft model using In Vivo Imaging System (IVIS).
RESULTS: Ex vivo-expanded gdT cells expressed NKG2D receptor on the cell surface and both TCRVg9, TCRVd2 lineage were well expanded. Activation of ex vivo-expanded gdT cell was confirmed by intracellular staining of granules, containing perforin and
